@article{d3d33faab5d24dfeb1a44679d22ce60a,
title = "Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.",
author = "Ajai Chari and Sarah Larson and Beata Holkova and Cornell, \{Robert F.\} and Cristina Gasparetto and Chatchada Karanes and Matous, \{Jeffrey V.\} and Ruben Niesvizky and Jason Valent and Lunning, \{Matthew A\} and Usmani, \{Saad Z.\} and Anderson, \{Larry D.\} and Lipo Chang and Yihua Lee and Yvonne Pak and Zeena Salman and Thorsten Graef and Elizabeth Bilotti and Saurabh Chhabra",
note = "This phase 1, dose-finding study investigated ibrutinib and carfilzomib ± dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (≥2 lines of therapy including bortezomib and an immunomodulatory agent). Of 43 patients enrolled, 74\% were refractory to bortezomib and 23\% had high-risk cytogenetics. No dose-limiting toxicities were observed.",
year = "2018",
month = apr,
day = "4",
doi = "10.1080/10428194.2018.1443337",
language = "American English",
volume = "59",
journal = "Leukemia \& Lymphoma",
number = "11",
}